Ajanta Pharma, Sun Pharma Poised for GLP-1 Opportunity in India Market Shift

India's GLP-1 market is experiencing a profound transformation following the patent expiry of semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. This shift from a premium, innovator-led segment to a competitive, volume-driven model is driving significant price erosion of nearly 85-90% and a surge in product launches, making therapies more accessible for obesity and metabolic management. As Siddhartha Khemka, Head of Research at Motilal Oswal Financial Services, highlights, companies like Ajanta Pharma and Sun Pharma are well-positioned to capitalize on this GLP-1 opportunity in India.

Understanding GLP-1 Medications and Their Role in Metabolic Health

GLP-1 receptor agonists like semaglutide mimic the glucagon-like peptide-1 hormone, which regulates blood sugar, slows gastric emptying, and reduces appetite. Clinically proven for type 2 diabetes and chronic weight management, these drugs address obesity's multi-system impacts, including cardiovascular risks and comorbidities. In India, where obesity affects an estimated 75-80 million people—a large proportion with co-morbid conditions—the patent expiry is pivotal, boosting semaglutide penetration in India as affordability improves.

Why This Market Shift Matters for Patients

Historically limited by high costs, GLP-1 therapies now offer broader access. Patients with BMI ≥30 or ≥27 with weight-related conditions may benefit, but consultation with endocrinologists or diabetologists is essential. Tools like Shotlee can help track symptoms, side effects such as nausea or gastrointestinal issues, and medication adherence for optimal outcomes.

The Structural Shift in India's Metabolic Therapy Landscape

Post-patent expiry, the market has transitioned rapidly. Demand is surging among millions needing structured obesity management, supported by broader specialist adoption and a growing prescriber base. Over the next 3-5 years, the market could scale to INR34-67 billion, driven by rising patient adoption and chronic therapy demand.

Price Erosion and Product Launch Surge

Prices have dropped 85-90%, enabling wider distribution and penetration. This volume-led growth contrasts with the prior innovator monopoly, fostering competition from over 10-15 players.

Expanding Prescriber Ecosystem Fuels Growth

Endocrinologists and diabetologists remain primary prescribers, but cardiologists, gastroenterologists, gynaecologists, and other specialists are increasingly involved due to obesity's multi-system effects. This broadening ecosystem accelerates awareness, referrals, and prescription volumes, ensuring long-term demand visibility for GLP-1 therapies in India.

Challenges in the Hyper-Competitive GLP-1 Arena

Intense competition has fragmented the market, imposing pricing pressures and commoditisation across premium, mid-tier, and mass-market tiers. Individual revenue gains stay modest at low single-digits for most, constrained by limited physician bandwidth—typically favoring just a handful of brands. This necessitates aggressive marketing, hiking promotional costs and risking diversion from established portfolios.

Safety Considerations for GLP-1 Use

While effective, GLP-1s carry risks like pancreatitis, thyroid tumors (in rodents), or gallbladder issues. Patients should monitor via regular check-ups; comparing to alternatives like older anti-obesity drugs, GLP-1s offer superior weight loss (10-15% body weight) but require lifestyle integration.

Emerging Trends: Rise of Next-Generation Therapies

Semaglutide builds category awareness, but newer molecules with superior efficacy gain faster physician preference, signaling potential long-term leadership shifts. This trend underscores innovation's role amid commoditisation.

Ajanta Pharma's Play in the GLP-1 Opportunity

Ajanta Pharma is preparing to launch generic semaglutide post Novo Nordisk's Ozempic/Wegovy patent expiry in India. This complements expansion in dermatology, pain management, and nephrology. Long-term growth stems from branded generics in India, US, Africa, and Asia, focusing on chronic therapies. Management anticipates mid-teens revenue growth with EBITDA margins around 27%, bolstered by Asia/Africa expansion, US pipeline, and added medical representatives.

Sun Pharma's Innovation Momentum

Sun Pharma's specialty and novel therapies scale robustly, with USD1b+ innovative sales (ex-milestones) providing US pricing resilience. Domestic formulations gain market share, while EM/ROW stability supports growth. In 3QFY26, revenues met estimates, EBITDA 6% ahead, driven by DF growth. Projections: EM+ROW to INR230b (FY25-28, 12% CAGR); specialty sales to USD1.7b (11% CAGR). DF outperformance, R&D intensity, and pipeline launches ensure earnings visibility.

Key Takeaways: What This Means for the GLP-1 Market

• Volume-Led Opportunity: Strong fundamentals with INR34-67B potential, but scale and execution are critical.
• Patient Guidance: Discuss GLP-1s with specialists if obese with comorbidities; weigh benefits vs. side effects.
• Investor Angle: Ajanta and Sun Pharma's strategies position them amid competition.
• Comparisons: GLP-1s outperform older therapies in efficacy; generics enhance access vs. branded Ozempic.

Conclusion: Navigating India's Evolving GLP-1 Landscape

The GLP-1 segment offers compelling growth underpinned by demand, yet pricing, competition, and differentiation challenges persist. Ajanta Pharma and Sun Pharma's focused execution could drive value capture. Patients: Prioritize doctor consultations for personalized metabolic health plans. For tracking progress, apps like Shotlee aid symptom and schedule management.

"Overall, the GLP-1 segment in India presents a compelling volume-led growth opportunity underpinned by strong demand fundamentals." – Siddhartha Khemka

(The author is Siddhartha Khemka, Head of Research - Wealth Management, Motilal Oswal Financial Services)

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)